CN106170554B - 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化 - Google Patents

过表达n-糖基化途径调节基因以调节重组蛋白的糖基化 Download PDF

Info

Publication number
CN106170554B
CN106170554B CN201480074585.XA CN201480074585A CN106170554B CN 106170554 B CN106170554 B CN 106170554B CN 201480074585 A CN201480074585 A CN 201480074585A CN 106170554 B CN106170554 B CN 106170554B
Authority
CN
China
Prior art keywords
day
cell
cells
culture
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480074585.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN106170554A (zh
Inventor
S.古普塔
S.康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53757626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106170554(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to CN202110902965.XA priority Critical patent/CN113774084B/zh
Publication of CN106170554A publication Critical patent/CN106170554A/zh
Application granted granted Critical
Publication of CN106170554B publication Critical patent/CN106170554B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01101—Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.101)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01094—Protein N-acetylglucosaminyltransferase (2.4.1.94)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01143—Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.143)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
CN201480074585.XA 2014-01-29 2014-12-11 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化 Active CN106170554B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110902965.XA CN113774084B (zh) 2014-01-29 2014-12-11 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933137P 2014-01-29 2014-01-29
US61/933,137 2014-01-29
PCT/US2014/069744 WO2015116315A1 (en) 2014-01-29 2014-12-11 Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110902965.XA Division CN113774084B (zh) 2014-01-29 2014-12-11 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化

Publications (2)

Publication Number Publication Date
CN106170554A CN106170554A (zh) 2016-11-30
CN106170554B true CN106170554B (zh) 2021-08-17

Family

ID=53757626

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480074585.XA Active CN106170554B (zh) 2014-01-29 2014-12-11 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化
CN202110902965.XA Active CN113774084B (zh) 2014-01-29 2014-12-11 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110902965.XA Active CN113774084B (zh) 2014-01-29 2014-12-11 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化

Country Status (14)

Country Link
US (3) US10227627B2 (enExample)
EP (1) EP3099806A1 (enExample)
JP (4) JP6474420B2 (enExample)
KR (3) KR102410393B1 (enExample)
CN (2) CN106170554B (enExample)
AU (3) AU2014380174C1 (enExample)
BR (1) BR112016017606A2 (enExample)
CA (1) CA2938079C (enExample)
CL (1) CL2016001900A1 (enExample)
EA (2) EA037565B1 (enExample)
IL (3) IL282517B (enExample)
MX (2) MX377780B (enExample)
SG (1) SG10201912081RA (enExample)
WO (1) WO2015116315A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CA3056011A1 (en) * 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
CN109576212B (zh) * 2018-12-14 2021-06-22 杭州奕安济世生物药业有限公司 高密度接种培养中种子细胞的培养方法及其应用
AU2019450349B2 (en) * 2019-06-10 2022-05-26 CHO Plus Inc. Cell lines for high level production of protein-based pharmaceuticals
EP4326766A1 (en) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CN113684322B (zh) * 2021-09-09 2024-01-23 上海药明生物技术有限公司 一种降低抗体类蛋白高聚甘露糖型水平的方法
CN114525252B (zh) * 2022-03-10 2023-12-01 广州源井生物科技有限公司 一种提高mda-mb-231单细胞克隆形成率的单克隆增强培养基与培养方法及其应用
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
EP0672141B1 (en) 1992-10-23 2003-05-14 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
AU2005229359C1 (en) 2004-03-05 2011-07-28 Patheon Holdings I B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2008087259A1 (en) * 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
WO2008154014A2 (en) * 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
TW201028431A (en) * 2008-10-31 2010-08-01 Lonza Ag Novel tools for the production of glycosylated proteins in host cells
EP2421892A1 (en) * 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
US20130196410A1 (en) * 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
BR112012025645A2 (pt) * 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
TW201209160A (en) * 2010-04-27 2012-03-01 Lonza Ag Improved glycosylation of proteins in host cells
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
BR112014016614B1 (pt) 2012-01-11 2022-02-01 Sigma-Aldrich Co. Llc Métodos para produzir uma célula deficiente em manosil (alfa-1,3-)-glicoproteína beta-1,2- nacetilglucosa-miniltransferase i (mgat1) e produzir uma proteína recombinante apresentando um ou mais resíduos de manose terminal

Also Published As

Publication number Publication date
IL270861A (en) 2020-01-30
CL2016001900A1 (es) 2017-05-12
SG10201912081RA (en) 2020-02-27
EA201691532A1 (ru) 2017-01-30
MX2016009911A (es) 2016-10-28
EA202190244A3 (ru) 2021-08-31
KR102301034B1 (ko) 2021-09-13
KR20160111943A (ko) 2016-09-27
AU2018264100A1 (en) 2018-12-06
KR20220086703A (ko) 2022-06-23
JP2022068365A (ja) 2022-05-09
AU2018264100B2 (en) 2020-07-23
CA2938079A1 (en) 2015-08-06
IL282517A (en) 2021-06-30
AU2014380174B2 (en) 2018-08-30
JP6474420B2 (ja) 2019-02-27
AU2014380174C1 (en) 2025-06-05
WO2015116315A1 (en) 2015-08-06
JP6797950B2 (ja) 2020-12-09
US10907186B2 (en) 2021-02-02
US20200277642A1 (en) 2020-09-03
US20190153496A1 (en) 2019-05-23
KR102519540B1 (ko) 2023-04-10
CN113774084B (zh) 2024-04-16
IL246914B (en) 2019-12-31
JP2017505620A (ja) 2017-02-23
IL282517B (en) 2022-07-01
AU2018264100C1 (en) 2025-06-05
CN106170554A (zh) 2016-11-30
KR20210114549A (ko) 2021-09-23
BR112016017606A2 (pt) 2017-10-10
JP7788307B2 (ja) 2025-12-18
AU2020239681C1 (en) 2025-06-05
EP3099806A1 (en) 2016-12-07
JP7034236B2 (ja) 2022-03-11
CA2938079C (en) 2022-10-11
CN113774084A (zh) 2021-12-10
IL270861B (en) 2021-05-31
US20190010532A1 (en) 2019-01-10
US10655156B2 (en) 2020-05-19
JP2021040638A (ja) 2021-03-18
JP2019088305A (ja) 2019-06-13
MX2020012356A (es) 2021-01-29
AU2020239681A1 (en) 2020-10-15
AU2020239681B2 (en) 2022-06-23
MX377780B (es) 2025-03-11
IL246914A0 (en) 2016-09-29
AU2014380174A1 (en) 2016-08-11
US10227627B2 (en) 2019-03-12
EA037565B1 (ru) 2021-04-14
KR102410393B1 (ko) 2022-06-16
EA202190244A2 (ru) 2021-05-31

Similar Documents

Publication Publication Date Title
JP7788307B2 (ja) 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現
AU2018201844C1 (en) Use Of Monensin To Regulate Glycosylation Of Recombinant Proteins
US10106829B2 (en) Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
HK1231928A1 (en) Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
HK1231928B (zh) 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化
EA047078B1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231928

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant